Adiponectin may mediate the beneficial effects of PPARγ agonists for the treatment of diabetes, as it is an insulin-sensitizing adipokine that affects hepatic glucose output and decreases triglyceride content in the liver and muscle [92]. Here, ADIPOQ is linked to diabetes mellitus.